OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli by Livermore, David M et al.
OXA-1 lactamase and non-susceptibility to penicillin/-lactamase inhibitor 1 
combinations among ESBL-producing Escherichia coli 2 
 3 
 4 
David M LIVERMORE1,2*, Michaela DAY1, Paul CLEARY3, Katie L HOPKINS1, Mark 5 
A TOLEMAN4, David W WAREHAM5, Camilla WIUFF6, Michel DOUMITH1 and Neil 6 
WOODFORD1  7 
 8 
 9 
1. Antimicrobial Resistance and Healthcare-Associated Infections Reference 10 
Unit, PHE National Infection Service, London, United Kingdom  11 
2. Norwich Medical School, University of East Anglia, Norwich, United Kingdom 12 
3. PHE Field Service, Liverpool, United Kingdom 13 
4. Cardiff University, Heath Park Campus, Cardiff, United Kingdom 14 
5. Blizard Institute, Queen Mary University London, United Kingdom 15 
6. Health Protection Scotland, Glasgow, United Kingdom 16 
 17 
 18 
 19 
 20 
Running Head: OXA-1 and penicillin/inhibitor resistance 21 
*Corresponding author: 22 
Bob Champion Research & Educational Building, 23 
James Watson Road, 24 
University of East Anglia, 25 
Norwich Research Park,  26 
NORWICH, NR4 7UQ 27 
 28 
 29 
Telephone: +44(0)1603 597568 30 
E-mail:  d.livermore@uea.ac.uk 31 
32 
Abstract 33 
Background. ESBL-producing Escherichia coli have expanded globally since the 34 
turn of the century and present a major public health issue.  Their in-vitro 35 
susceptibility to penicillin/inhibitor combinations is variable, and clinical use of 36 
these combinations against ESBL producers remains controversial.  We 37 
hypothesised that this variability related to co-production of OXA-1 penicillinase.  38 
Methods.  During a national study we collected 293 ESBL E. coli from 39 
bacteraemias, determined MICs by BSAC agar dilution and undertook genomic 40 
sequencing with Illumina methodology.  Results.  The collection was dominated 41 
by ST131 (n=188 isolates) and blaCTX-M-15 (present in 229 isolates, 78.2%); over 42 
half the isolates (159/293, 54.3%) were ST131 with blaCTX-M-15.  blaOXA-1 was found 43 
in 149 ESBL producers (50.9%) and blaTEM-1/191 in 137 (46.8%).  Irrespective of 44 
whether all isolates were considered, or ST131 alone, there were strong 45 
associations (p <0.001) between co-carriage of blaOXA-1 and reduced susceptibility 46 
to penicillin/inhibitor combinations, whereas there was no significant association 47 
with co-carriage of blaTEM-1/191. For piperacillin/tazobactam the mode MIC rose 48 
from 2 mg/L in the absence of blaOXA-1 to 8-16 mg/L in its presence; for co-49 
amoxiclav the shift was smaller, from 8 to 16 mg/L, but crossed the breakpoint.   50 
blaOXA-1 was strongly associated with co-carriage also of aac(6’)-Ib-cr, which 51 
compromises amikacin and tobramycin.  Conclusion.  Co-carriage of OXA-1, a 52 
penicillinase with weak affinity for inhibitors, is a major arbiter of resistance to 53 
piperacillin/tazobactam and co-amoxiclav in E. coli and is commonly associated 54 
with co-carriage of aac(6’)-Ib-cr, which narrows aminoglycoside options. 55 
56 
Introduction 57 
Penicillin/-lactamase inhibitor combinations account for 20% of in-patient antibiotic 58 
use in UK hospitals,1 and for a greater proportion of parenteral use.  Whilst these 59 
combinations are effective in many infections due to -lactamase producers, debate 60 
persists on their efficacy against those with ESBLs, along with disagreements on 61 
breakpoints.2   62 
Tazobactam and clavulanate inhibit TEM, SHV and CTX-M ESBLs,3-5 in some 63 
cases more efficiently than classical penicillinases.6  Nevertheless, surveys find that 64 
sizeable proportions of ESBL-producing Escherichia coli and Klebsiella pneumoniae 65 
are non-susceptible to piperacillin/tazobactam and amoxicillin/clavulanate, as are 66 
minorities of isolates with classical TEM and SHV penicillinases.7-9 The issue is 67 
complicated by differing breakpoints for piperacillin/tazobactam between EUCAST 68 
(S <8, R >16 mg/L) and CLSI (S <16, R >64 mg/L) and different testing modalities 69 
for amoxicillin/clavulanate, where EUCAST advocates a fixed 2 mg/L clavulanate but 70 
CLSI prefers a 2:1 amoxicillin/clavulanate ratio, giving breakpoints of 8+2 and 8+4 71 
mg/L respectively.    72 
Clinical studies on the efficacy of penicillin/inhibitor combinations against 73 
ESBL producers have given contradictory results.10   Both EUCAST and CLSI take 74 
the view of ‘report as found’,11 and one bacteraemia study (not specifically of ESBL 75 
producers) found good outcomes for piperacillin/tazobactam against 76 
Enterobacteriaceae up to an MIC of 16 mg/L.12 Another study however found good 77 
outcomes up to an MIC of  16 mg/L only if the bacteraemia had a urinary origin 78 
whereas there were high failure rates if the MIC was above 2 mg/L and the 79 
bacteraemia originated elsewhere.13 The recent MERINO trial, investigating 80 
bacteraemia due to ceftriaxone-resistant, piperacillin/tazobactam-,susceptible’, E. 81 
coli and K. pneumoniae found 12.3%  30-day mortality for patients treated with 82 
piperacillin/tazobactam versus 3.7% for meropenem (p = 0.002).14 83 
Reasons for variable resistance to penicillin/inhibitor combinations among 84 
ESBL producers are under-researched.   Factors demonstrated for at least some 85 
isolates include: (i) production of multiple lactamases,15 sometimes including 86 
poorly-inhibited penicillinases such as OXA-1,16,17 (ii) hyper-production of target 87 
lactamases18,19 and (iii) impermeability.20  We explored the role of OXA-1 enzyme 88 
in a national collection of genomically-sequenced ESBL E. coli from bloodstream 89 
infections. 90 
 91 
Materials and Methods 92 
Isolates 93 
Isolates were from human bloodstream infections and were collected in 2013-2014 94 
during a national study comparing ESBL E. coli from human and non-human 95 
sources.  Collecting sites in London (1 hospital), East Anglia (5 hospitals), Northwest 96 
England (2 hospitals), Wales (2 hospitals) and Scotland (2 hospitals) incubated 97 
blood cultures on automated BacT/Alert (bioMérieux, Basingstoke, UK) systems and 98 
performed identification and susceptibility testing according to local protocols. 99 
Consecutive isolates identified by these local methods as ESBL-producing E. coli 100 
were sub-cultured to agar slopes and sent to PHE Colindale. On receipt, their 101 
identity was confirmed by MALDI-ToF (Bruker Daltonics, Bremen, Germany) and 102 
blaCTX-M genes were sought by PCR,21 with isolates found positive accepted as 103 
ESBL producers.   Isolates lacking blaCTX-M were screened for blaTEM and blaSHV by 104 
PCR22 and, if positive, subjected to double disc synergy tests between 105 
amoxicillin/clavulanate (20+10 g; Oxoid, Basingstoke, UK) and each of cefepime, 106 
cefotaxime and ceftazidime (all 30 g), with a positive result for any cephalosporin 107 
being taken to indicate ESBL activity.23 Confirmation of ESBL production came from 108 
comprehensive susceptibility testing and sequencing, as below.  109 
 110 
Antibiotics and susceptibility testing 111 
Except for clavulanate (GlaxoSmithKline, Brentford, UK) and tazobactam (Alfa 112 
Aesar, Heysham, UK), antibiotics were obtained from Sigma, Poole, UK.  MICs were 113 
determined by BSAC agar dilution using IsoSensitest agar (Oxoid).24  Tazobactam 114 
was used at a fixed 4 mg/L and clavulanate at a fixed 2 mg/L, in keeping with current 115 
EUCAST guidance. 116 
 117 
WGS 118 
DNA libraries were prepared using the NexteraXT method and sequenced to >30X 119 
coverage with a standard 2x100 base protocol on a HiSeq 2500 instrument (Illumina, 120 
San Diego, CA, USA). Reads were trimmed using Trimmomatic to remove low-121 
quality data, then assembled into contigs using VelvetOptimiser25 with k-mer values 122 
from 55 to 75. Strains were identified by mapping reads against ST-specific E. coli 123 
sequences using the MOST software.26  124 
 Antibiotic resistance genes were sought in contigs by BLASTn, or by mapping 125 
reads against reference sequences in the Comprehensive Antibiotic Resistance 126 
Database and parsing the variant calling format (VCF) file generated by SAMtools 127 
mpileup.27 This process was automated into the ‘Genefinder’ pipeline created by 128 
PHE Bioinformatics (M. Doumith, PHE, unpublished). The location of resistance 129 
determinants on assembled contigs was checked by Blastn. 130 
 131 
Statistics 132 
We calculated relative risks and assessed potential interactions using the Woolf test 133 
for homogeneity. We used Pearson chi-square tests to assess significance of 134 
associations at p value equal to 0.05. 135 
 136 
Results 137 
ESBL confirmation and STs 138 
Sixty-six ESBL producers were confirmed from bacteraemic patients in East Anglia, 139 
55 from London, 61 from Northwest England, 37 from Scotland and 74 from Wales, 140 
giving a geographically representative collection of 293 isolates.  These isolates 141 
included 39 known STs, one non-typeable organism, and five new STs.  The well-142 
known international ST131 lineage28,29 dominated, with 188 representatives (64.2%); 143 
other STs with >2 representatives were ST38 (n=17) ST648 (n=16), ST405 (n=9), 144 
ST73 (n=6), ST69 (n=4), ST636 (n=4), ST95 (n=3), ST10 (n=3) and ST1193 (n=3).  145 
CTX-M-15 lactamase was the predominant ESBL, with its gene present in 229 146 
(78.2%) isolates, whereas 27 had blaCTX-M-27, 20 had blaCTX-M-14, four had blaCTX-M-1, 147 
three had blaCTX-M-3 and one had blaCTX-M-9.  Three isolates had blaSHV-12 and one had 148 
blaSHV-31 both of which encode recognised SHV-ESBLs; one isolate, with an ESBL 149 
phenotype, solely had blaTEM-117 and eight, all carrying other well-known ESBL 150 
determinants, also had blaTEM-191, encoding a TEM variant with an uncertain status, 151 
which was not counted as an ESBL here.30   Four isolates carried two ESBL genes 152 
in combination; many more also carried genes for classical penicillinases along with 153 
those for ESBLs: in particular blaTEM-1 was present in 129/293 isolates (or 137/293 if 154 
those with TEM-191 were included, 46.8%) and blaOXA-1 (or, in one case, a variant 155 
with a conservative Ile187Leu modification) was found in 149/293 (50.9%). blaTEM-1 156 
accompanied many different ESBL genes but blaOXA-1 was always together with 157 
blaCTX-M-15 along, in one isolate, with blaCTX-M-14.  Two isolates had acquired 158 
blaCMY/ampC genes together with their ESBLs, and two had blaOXA-9.  Among the 159 
ST131 isolates, the great majority (159/188, 84.6%) had blaCTX-M-15, though 24 had 160 
blaCTX-M-27 and 5 had blaCTX-M-14 alone or in combination; 116 had blaOXA-1  whilst 76 161 
had blaTEM-1/191. 162 
The lactamase combinations found in the whole collection and among the 163 
ST131 isolates are detailed in Table 1, which also shows the corresponding MIC 164 
distributions for piperacillin/tazobactam and amoxicillin/clavulanate.   165 
Whenever blaOXA-1 was present, alone or together with blaTEM-1/191, the MIC 166 
distributions of penicillin/inhibitor combinations were raised, with the mode 167 
increasing from 2 mg/L to 8 or (depending on the particular sub-set) 16 mg/L for 168 
piperacillin/tazobactam and from 4 or 8 to 16 mg/L for amoxicillin/clavulanate.  169 
These shifts in modal MIC were apparent for both the whole collection and for 170 
ST131, when this was reviewed separately.  No such shift was seen when ESBLs 171 
were accompanied only by TEM-1/191 enzyme.   172 
Whilst these blaOXA-1-related MIC shifts were small in absolute terms, their 173 
effect was to move the peak of the distribution for piperacillin/tazobactam from within 174 
the susceptible range to around the breakpoint, whilst the mode for 175 
amoxicillin/clavulanate moved across the breakpoint.   Overall, 62/63 (98.4%) 176 
isolates with ESBL genes alone were susceptible to piperacillin/tazobactam at 8 177 
mg/L as were 75/79 (94.9%) that had an ESBL gene together with only blaTEM-1/191 178 
whereas the proportion susceptible fell to 67/91 (73.6%) among those with an ESBL 179 
plus blaOXA-1 and to 33/58 (56.9%) for those with an ESBL plus both blaOXA-1 and 180 
blaTEM-1/191. For amoxicillin/clavulanate, 44/63 (69.8%) were susceptible when the 181 
ESBL gene was present alone and 50/79 (63.3%) when it was accompanied by 182 
blaTEM-1/191 whilst these proportions fell to 21/91 (23.1%) for isolates with blaOXA-1 183 
together with their ESBL gene and to 7/58 (12.1%) when both blaOXA-1 and blaTEM-184 
1/191 were present.  When the ST131 organisms were considered alone, non-185 
susceptibility to piperacillin/tazobactam at 8 mg/L was seen in 39/116 (33.6%) 186 
isolates where blaOXA-1 was present compared with 2/72 (2.8%) where it was absent; 187 
corresponding proportions for amoxicillin/clavulanate were 94/116 (81.0%) 188 
compared with 24/72 (33.3%) respectively. 189 
Both for the whole collection and the ST131 isolates, the relative risks of non-190 
susceptibility to penicillin/-lactamase inhibitor combinations were highly significant 191 
for OXA-1 (p <0.001) but non-significant for TEM-1/191 (Table 2).  Although the 192 
modal MIC was one doubling dilution higher for the isolates that had both OXA-1 193 
and TEM-1/191 than for those with only OXA-1, there was no statistical evidence of 194 
interaction between OXA-1 and TEM-1/191 to further augment resistance. 195 
Occasional non-susceptibility to piperacillin/tazobactam was seen in isolates 196 
lacking both blaOXA-1, as in 1/26 with blaCTX-M-15 alone (MIC 32 mg/L) and 4/65 with 197 
blaCTX-M-14/15 together with blaTEM-1 (MICs 16-32 mg/L), also (unsurprisingly) in both 198 
isolates with acquired blaCMY gene, neither of which had blaOXA-1.  On the other hand 199 
10/58 isolates with blaCTX-M-15 plus both blaTEM-1/191 and blaOXA-1 remained fully 200 
susceptible to piperacillin/tazobactam, with MICs of 2-4 mg/L.  201 
 202 
Linkage of blaOXA-1, aac(6’)-Ib and other resistance determinants 203 
There was a striking association between the carriage of blaOXA-1 and of the 204 
aminoglycoside-acetyl transferase determinant aac(6’)-Ib, which was almost always 205 
(146/148 cases) present as its aac(6’)-Ib-cr variant, encoding an enzyme that 206 
acetylates some fluoroquinolones as well as the normal aminoglycoside substrates. 207 
This association is illustrated both for the whole collection and for the major -208 
lactamase-defined subgroups of ST131 isolates in Table 3.  Overall, 147 of the 149 209 
isolates with blaOXA-1 also had aac(6’)-Ib-cr, compared with 1/144 of those that 210 
lacked blaOXA-1. Other resistance genes associated with blaOXA-1 across the whole 211 
collection were aac(3’)-IIa, aadA5, sul1, dfrA17 and tet(A) (Table 4). catB3, encoding 212 
a chloramphenicol acetyltransferase, also was widely present in association with 213 
blaOXA-1 (not shown) but was truncated and surmised to be non-functional.  214 
Conversely, sul2, strA, strB and aac(3’)-IId were more prevalent among isolates that 215 
lacked blaOXA-1.  The association between blaOXA-1 and aac(6’)-Ib-cr remained clear 216 
when ST131 isolates were considered alone, but aac(3’)-IIa, aadA5, sul1, dfrA17 217 
and tet(A) also were widespread among ST131 isolates with blaCTX-M-27 alone or with 218 
blaCTX-M-15 combined with either or both of blaTEM and/or blaOXA-1.  strA/B and sul2 219 
genes remained negatively associated with blaOXA-1 among the ST131 isolates 220 
(Table 4). 221 
 Resistance tracked with causative genes. Thus, 141/148 isolates with aac(6’)-222 
Ib-cr were resistant to tobramycin and 69 had reduced susceptibility to amikacin, 223 
with MICs >4 mg/L, though non-susceptibility on EUCAST criteria (MIC >8 mg/L) 224 
was seen for only 25/148.  Tobramycin resistance was not, however, exclusive to 225 
isolates with aac(6’)-Ib-cr also being associated with aac(3)-II variants when these 226 
were present independently of aac(6’)-Ib-cr. Overall non-susceptibility rates for 227 
blaOXA-1-positive compared with blaOXA-1–negative isolates were: tobramycin (MIC >2 228 
mg/L) 94.6% versus 31.2%; amikacin (MIC >8 mg/L) 16.8% versus 2.8%; 229 
ciprofloxacin (MIC >0.25 mg/L) 97.2% versus 70.7%; tetracycline (MIC >8 mg/L) 230 
83.4% versus 70.7%; sulphonamides; (MIC >256 mg/L) 85.5% versus 76.4%; 231 
trimethoprim (MIC >2 mg/L) 89.6% versus 77.8% and streptomycin (MIC >8 mg/L) 232 
58.6% versus 71.1%.  Truncated catB3 was not associated with chloramphenicol 233 
resistance confirming its non-functionality. 234 
 235 
Discussion 236 
Although a link between OXA-1 enzyme and reduced susceptibility or resistance to 237 
penicillin/inhibitor combinations has been suggested previously,16,17 both for ESBL-238 
producing and non-producing Enterobacteriaceae, these assertions do not appear to 239 
have been tested with sizeable and geographically diverse collections of bacteria, let 240 
alone using those characterised by WGS.  One study asserting this linkage only 241 
found OXA-1 in 12/59 piperacillin/tazobactam-resistant isolates and, since many of 242 
the remainder were resistant to carbapenems, it is likely that they had other 243 
mechanisms besides OXA-1 enzyme.16  244 
 Here we found that MICs of piperacillin/tazobactam for ESBL E. coli with 245 
OXA-1 penicillinase clustered around or just above the 8+4 mg/L breakpoint, and 246 
that those of amoxicillin/clavulanate were narrowly above its 8+2 mg/L breakpoint.  247 
By contrast, and irrespective of whether they co-produced TEM-1 enzyme, MICs for 248 
ESBL E. coli lacking OXA-1 enzyme were almost all clearly within the susceptible 249 
range for piperacillin/tazobactam, at around 2+4 mg/L, and narrowly within it for 250 
amoxicillin/clavulanate, clustering at 4-8 mg/L.  A few individual isolates lay outside 251 
these generalisations, either (i) lacking OXA-1 enzyme but being resistant to 252 
penicillin/-lactamase inhibitor combinations, or (ii) possessing the gene for this 253 
enzyme and remaining susceptible.  Anomalous resistance perhaps may reflect low 254 
permeability, up-regulated efflux, copious ESBL production or elevated expression of 255 
chromosomal AmpC; anomalous susceptibility may reflect high permeability, weak 256 
efflux or non-expression of blaOXA-1 or other genes. Nevertheless, the general 257 
relationship between raised MICs for the inhibitor combinations and carriage of 258 
blaOXA-1 were clear and individual anomalies were not pursued further.   259 
It should be cautioned that the ESBL accompanying OXA-1 was always CTX-260 
M-15, and we cannot be certain that identical behaviour would be seen with other 261 
ESBLs. However there is no obvious reason why the ESBL type should affect the 262 
poor inhibition of OXA-1, and CTX-M-15 is considerably the commonest ESBL in the 263 
UK and worldwide.29 In the absence of OXA-1, modal MICs of the penicillin/inhibitor 264 
combinations were consistent irrespective of whether CTX-M-15 or another ESBL 265 
was produced. These findings have clear implications for penicillin/inhibitor 266 
combinations but not for newer cephalosporin/inhibitor combinations (e.g. 267 
ceftolozane/tazobactam and ceftazidime/avibactam), as these use cephalosporins 268 
that are stable to OXA-1 enzyme. Cefepime is somewhat labile to OXA-1,31,32 but 269 
prospective cefepime/tazobactam combinations appear to retain near universal 270 
activity against ESBL producers, many of which likely also carried OXA-1.33     271 
 The therapeutic challenges posed by bacteria carrying OXA-1 enzyme 272 
together with CTX-M-15 are exacerbated by frequent co-carriage of aac(6’)-Ib, 273 
(almost always as its aac(6’)-Ib-cr variant, conferring resistance to tobramycin).  274 
AAC(6’)-Ib also acetylates amikacin and, although MICs for producers commonly 275 
remained below the breakpoint, current EUCAST advice remains to avoid the drug 276 
wherever this enzyme is present.11 Resistance rates to ciprofloxacin, 277 
sulphonamides, trimethoprim and tetracycline also were slightly higher among OXA-278 
1-positive than OXA-1-negative ESBL producers though, unlike for tobramycin and 279 
the penicillin/inhibitor combinations, they were high in both groups. 280 
Co-carriage of blaOXA-1 with blaCTX-M-15 has been previously established in UK 281 
variants of E. coli ST131, where it was associated with IncF plasmids pEK499 282 
(117,536 bp) and pEK516 (64,471 bp) 34,35 Plasmid pEK516 had blaOXA-1 and blaCTX-283 
M-15 separated by a 7,457-bp region that encoded catB4, aac(3’)-IIa and tunicamycin 284 
resistance genes; aac(6’)-1b-cr was immediately upstream of blaOXA-1 and a class 1 285 
integron containing dfrA17, aadA5 and sul1 genes was present 1.7-kb upstream of 286 
blaCTX-M-15. Similar organisation is seen in the common Canadian blaCTX-M-15 plasmid 287 
pC15-1a.36   In the case of pEK499, which differed from pEK516 in having an IS26-288 
mediated deletion of aac(3’)-IIa and the tunicamycin resistance genes, blaOXA-1 and 289 
blaCTX-M-15 were only 4037 bp apart. Given their earlier prevalence and the similarity 290 
of the present resistance profiles it seems likely that the same or very similar 291 
plasmids to pEK499 and pEK516 remain prevalent in bloodstream ST131 E. coli 292 
from the UK. This could not be definitively proven here because the presence of 293 
multiple copies of IS26 precluded assembly from short-read sequencing data; 294 
nevertheless we could confirm that blaOXA-1, aac(6’)-1b-cr and the truncated catB3 295 
were demonstrably linked on the same ~2-3 kb contig in at least 139 of the 149 296 
isolates that had both blaOXA-1 and blaCTX-M-15. 297 
 In conclusion, these data suggest that the frequent question: ‘Are 298 
penicillin/inhibitor combinations active against ESBL producers?’ is misplaced.  The 299 
more pertinent query is ‘Does my ESBL-producing isolate also have OXA-1 300 
enzyme?’  The findings have implications for diagnostic development. We have 301 
shown elsewhere that multiplex tandem PCR can be used to seek bacterial 302 
resistance genes in urine from UTI patients, giving accurate results 24-48h before 303 
susceptibility test data become available.37  A panel that targeted E. coli generically, 304 
E. coli ST131 specifically, blaOXA-1, blaCTX-M, aac(6’)-1b, common gentamicin 305 
resistance determinants and the gyrA mutations responsible for fluoroquinolone 306 
resistance has the potential to provide a useful guide for the treatment of patients 307 
being admitted to hospital with upper UTIs and urosepsis.  Detection of ST131 and 308 
the blaOXA-1, blaCTX-M, aac(6’)-Ib-cr trio should give a steer towards early carbapenem 309 
use in the severely ill patient, whilst the absence of blaOXA-1 should increase the 310 
confidence with which penicillin/inhibitor combinations might be used. 311 
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Table 1. -Lactamase profiles and penicillin/inhibitor MICs among all ESBL E. coli from bloodstream infections (n=293) and ST131 480 
isolates (n=188) 481 
 No isolates with indicated MIC (mg/L) 
Total 
% 
Susceptible 
at 8 mg/L 
 <1 2 4 8 16 32 64 >64 
PIPERACILLIN/TAZOBACTAM            
All isolates with ESBL alone           
CTX-M-15 2 13 7 3  1   26 96.2 
CTX-M-27 3 12 5 2     22 100.0 
CTX-M-1 1 5             6 100.0 
CTX-M-14  3 2      5 100.0 
CTX-M-3  1       1 - 
CTX-M-9  1       1 - 
CTX-M-15; CTX-M-3    1      1 - 
TEM-117-p*a  1       1 - 
Total 6 36 15 5 0 1 0 0 63 98.4 
           
All isolates with ESBL plus TEM-1, no OXA-1           
CTX-M-15;TEM-1/191 6 19 20 3 2 1   51 94.1 
CTX-M-14;TEM-1  6 4 3 1    14 92.9 
CTX-M-27;TEM-1  2 2 1     5 - 
CTX-M-1;TEM-1  2 1      3 - 
SHV-12;TEM-1/191  2 1      3 - 
CTX-M-3;TEM-1    1      1 - 
CTX-M-24;TEM-1  1       1 - 
CTX-M-1;OXA-9;SHV-31;TEM-1    1      1 - 
Total 6 32 30 7 3 1 0 0 79 94.9 
           
All isolates with ESBL plus OXA-1, no TEM-1           
CTX-M-15;OXA-1 b 2 8 24 33 13 5 2 2 89 74.2 
CTX-M-15; CTX-M-3;OXA-1     1     1 - 
CTX-M-15;CTX-M-14;OXA-1    1      1 - 
 Total 0 8 25 34 13 5 2 2 91 73.6 
           
All isolates with ESBL plus TEM-1 and OXA-1           
CTX-M-15;OXA-1;TEM-1/191  3 7 23 19 5   57 57.9 
CTX-M-15;OXA-1;OXA-9;TEM-191-p*      1    1 - 
Total 0 3 7 23 20 5 0 0 58 56.9 
           
All isolates with ESBL plus AmpC           
CTX-M-15;CMY-4-p*         1 1 - 
CTX-M-15;CMY-42         1 1 - 
Total 0 0 0 0 0 0 0 2 2 0.0 
           
Major groups of ST131 isolates           
CTX-M-15 1 5 3 2  1   12 91.7 
CTX-M-27 3 12 5 2     22 100.0 
CTX-M-15;TEM-1/191 2 15 10 2  1   30 96.7 
CTX-M-15;OXA-1 1 7 18 29 11 4 2 2 74 74.3 
CTX-M-15;OXA-1;TEM-1/191  2 6 13 15 4   40 52.5 
           
Minor groups of ST131 isolates           
CTX-M-14   2 1           3 - 
CTX-M-27;TEM-1  1  1     2 - 
CTX-M-14;TEM-1  1       1 - 
CTX-M-15; CTX-M-3    1      1 - 
CTX-M-15;CTX-M-14;OXA-1    1      1 - 
CTX-M-15;OXA-1;OXA-9;TEM-191-p*      1    1 - 
CTX-M-3;TEM-1    1      1 - 
           
           
AMOXICILLIN/CLAVULANATE           
All isolates with ESBL alone           
CTX-M-15  1 5 12 5 2 1  26 69.2 
CTX-M-27    9 5 6 1 1  22 63.6 
CTX-M-1    1 5         6 - 
CTX-M-14     4 1    5 - 
CTX-M-3     1     1 - 
CTX-M-9     1     1 - 
CTX-M-15; CTX-M-3      1    1 - 
TEM-117-p*      1    1 - 
Total 0 1 15 28 14 3 2 0 63 69.8 
           
All isolates with ESBL plus TEM-1, no OXA-1           
CTX-M-15;TEM-1/191    12 27 9 3   51 76.5 
CTX-M-14;TEM-1     3 10 1   14 21.4 
CTX-M-27;TEM-1    1 2 2    5 - 
CTX-M-1;TEM-1     2 1    3 - 
SHV-12;TEM-1/191     2 1    2 - 
CTX-M-3;TEM-1      1    1 - 
CTX-M-24;TEM-1     1     1 - 
CTX-M-1;OXA-9;SHV-31;TEM-1      1    1 - 
Total 0 0 13 37 25 4 0 0 79 63.3 
           
All isolates with ESBL plus OXA-1, no TEM-1           
CTX-M-15;OXA-1b    2 19 55 13   89 23.9 
CTX-M-15; CTX-M-3;OXA-1      1    1 - 
CTX-M-15;CTX-M-14;OXA-1      1    1 - 
Total 0 0 2 19 57 13 0 0 91 23.1 
           
All isolates with ESBL plus TEM-1 and OXA-1           
CTX-M-15;OXA-1;TEM-1/191    1 5 33 18   57 10.5 
CTX-M-15;OXA-1;OXA-9;TEM-191-p*     1     1 - 
Total 0 0 1 6 33 18 0 0 58 12.1 
           
All isolates with ESBL plus AmpC           
CTX-M-15; CMY-42        1 1 - 
CTX-M-15; CMY-4-p        1 1 - 
Total 0 0 0 0 0 0 0 2 12 0 
           
Major groups of ST131 isolates           
CTX-M-15   2 5 2 2 1  12 58.3 
CTX-M-27   9 5 6 1 1  22 63.6 
CTX-M-15;TEM-1/191   5 17 6 2   30 73.3 
CTX-M-15;OXA-1   2 15 46 11   74 23.0 
CTX-M-15;OXA-1;TEM-1/191   1 3 22 14   40 10.0 
Minor groups of ST131 isolates           
CTX-M-14    3         3 - 
CTX-M-27;TEM-1   1  1    2 - 
CTX-M-14;TEM-1    1     1 - 
CTX-M-15; CTX-M-3     1    1 - 
CTX-M-15;CTX-M-14;OXA-1      1    1 - 
CTX-M-15;OXA-1;OXA-9;TEM-191-p*    1     1 - 
CTX-M-3;TEM-1     1    1 - 
 482 
 483 
a p* Enzyme is defined from a partial sequence, preventing confident precise matching. 484 
b  Includes one isolate with an OXA-1 sequence variant, with Ile187Leu.485 
Table 2. Risk of non-susceptibility to penicillin/-lactamase inhibitor combinations in relation to the presence of secondary -486 
lactamases 487 
  Piperacillin/tazobactam  Amoxicillin/clavulanate 
  
Secondary -
lactamase 
Relative risk 
of MIC  
>8 mg/L 
95% LCI 95% UCI p value  
Relative 
risk of MIC  
> 8 mg/L 
95% LCI 95% UCI p value 
All ESBL E. 
coli isolates OXA-1a 6.49 3.03 13.88 <0.001  2.34 1.85 2.96 <0.001 
 TEM-1/191 1.32 0.81 2.14 0.257  1.00 0.82 1.22 0.992 
 OXA-1 + TEM-1/191 3.49 2.22 5.48 <0.001  1.72 1.47 2.02 <0.001 
  (p value for homogeneity = 0.33)    (p value for homogeneity = 0.34)  
ST131 ESBL 
E. coli isolates OXA-1 12.10 3.01 48.61 <0.001  2.43 1.73 3.41 <0.001 
 TEM-1/191 1.58 0.92 2.71 0.094  0.96 0.77 1.21 0.741 
 OXA-1 + TEM-1/191 3.41 2.06 5.66 <0.001  1.57 1.31 1.89 <0.001 
   (p value for homogeneity = 0.47)     (p value for homogeneity = 0.17)   
 488 
LCI = lower confidence interval; UCI = upper confidence interval; p values shown are for chi-square tests except where indicated; p 489 
value for homogeneity indicates significance of interaction between OXA-1 and TEM-1 according to the Woolf test 490 
a Includes one isolate with an OXA-1 sequence variant, with Ile187Leu 491 
Table 3. Aminoglycoside and fluoroquinolone resistance among major ST131 groups 492 
 493 
 No with  
 n 
aac(6’)
-1ba 
aac(3)-
IIa 
aac(3)-
IId 
ant(2”) 
-Ia 
aadA
5 
aadA
1 
aadA
2 strA strBb 
dfrA
17 
dfrA
12 
Other 
dfr tet(A)c sul1 sul2 
catA 
1 
Whole collection (n=293) 
OXA-1 positive 149 147 88 7 6 113 6 9 25 26 113 10 14 121 122 31 19 
OXA-negative 144 1 18 18 1 65 17 13 81 81 68 8 33 85 78 83 10 
                  
Major ST131 groups (n=178 from a total of 188 ST131 isolates, see Table 1) 
CTX-M-15 12 0 1 0 0 6 0 2 4 4 6 2 2 4 9 4 0 
CTX-M-27 22 0 0 0 0 17 0 0 17 17 17 0 0 17 18 17 0 
CTX-M-15; TEM-1 30 0 11 9 0 19 0 4 20 20 19 4 1 20 22 20 2 
CTX-M-15; OXA-1 74 73 34 0 2 67 0 4 4 4 67 4 0 62 70 9 0 
CTX-M-15; OXA-1; TEM-1 40 39 27 6 4 26 0 5 9 9 26 5 2 29 30 10 5 
 494 
a Almost always (146/148 cases) as the aac(6’)-Ibcr variant 495 
b Including aph(6)-Id 496 
c Including tet(A)-1 497 
 498 
 499 
  500 
Table 4. Relative likelihood of OXA-1 being present in relation to the presence of other resistance genes 501 
 502 
 All E. coli isolates  ST131 E. coli isolates 
Resistance 
gene 
Relative risk 
of OXA-1 
presence 
95% 
LCI 
95% 
UCI 
p 
value 
 
Relative risk 
of OXA-1 
presence 
95% 
LCI 
95% 
UCI 
p 
value 
aac(6’)-Ib 72.01 18.18 285.21 <0.001  37.00 9.43 145.18 <0.001 
aac(3’)-IIa 2.55 2.04 3.18 <0.001  1.79 1.44 2.23 <0.001 
aadA5 1.97 1.48 2.62 <0.001  1.32 0.98 1.78 0.047 
sul1 2.13 1.52 2.99 <0.001  1.38 0.94 2.03 0.058 
dfrA17  1.94 1.45 2.60 <0.001  1.43 1.04 1.96 0.013 
sul2 0.41 0.30 0.57 <0.001  0.39 0.26 0.57 <0.001 
strA 0.36 0.25 0.51 <0.001  0.29 0.18 0.47 <0.001 
strB 0.37 0.26 0.52 <0.001  0.29 0.18 0.47 <0.001 
tet(A) 1.83 1.32 2.53 <0.001  1.43 1.04 1.95 0.012 
aac(3’)-IId 0.53 0.28 1.00 0.017  0.63 0.34 1.18 0.071 
 503 
LCI = lower confidence interval; UCI = upper confidence interval; p values shown for chi-square tests except where indicated. 504 
 505 
‘OXA-1’ includes one isolate with an Ile187Leu sequence variant. 506 
